Austrian assessment of prevalence of unknown prediabetes and diabetes as well as standard of care in people with established type 2 diabetes in primary care in Austria – the AUSTRO-PROFIT-Trial

Austrian assessment of prevalence of unknown prediabetes and diabetes as well as standard of care in people with established type 2 diabetes in primary care in Austria – the AUSTRO-PROFIT-Trial - AUSTRO-PROFIT TRIAL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027951

Enrollment

2500

Registered

2023-04-25

Start date

2021-04-09

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11

Interventions

Group 1: Each GP participating in the study will complete an (electronic) Case Report Form with data of the first 14 patients older than 50 years suffering from type 2 diabetes after launching the stu

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Cohort 1 (DM2) 1) Known diagnosis of type 2 diabetes mellitus 2) Written informed consent 3) Willing to fill out the questionnaires (IPAQ and SF36) 4) > 50 years old Cohort 2 ("Gesundenuntersuchung") 1) > 50 years old 2) Written informed consent 2) Willing to fill out the questionnaires (IPAQ and SF36)

Exclusion criteria

Exclusion criteria: Cohort 1 (DM2) Any type of diabetes other than type 2 diabetes (e.g. type 1 diabetes, LADA, type 3c diabetes) Cohort 2 ("Gesundenuntersuchung") Known diagnosis of diabetes mellitus (any type)

Design outcomes

Primary

Measure	Time frame
Primary outcome diabetes cohort The primary objective of the register is to characterize standard medical care and co-morbidities of people with type 2 diabetes in a primary care setting in Austria. Primary outcome measures: -Laboratory parameters: HDL-cholesterol, LDL-cholesterol, Triglycerides, Total cholesterol, HbA1c, Fasting plasma glucose, Creatinine, eGFR, Alanin-Aminotransferase (ALT), Aspartate-Aminotransferase (AST) -Medication :Glucose lowering medication, Lipid-lowering medication, Antihypertensive treatment, Antiplatelet therapy, Anticoagulants -Anthropometric and demographic data :Age, Sex, Weight, Height, Blood Pressure, Diabetes Duration, Smoking Behaviour -Comorbidities: Evaluation of circulatory abnormalities (peripheral vascular disease, stroke, coronary artery disease), arterial hypertension, heart failure, retinopathy, neuropathy, nephropathy (microproteinuria, macroproteinuria, nephrotic range proteinuria, renal failure), erectile dysfunction and diabetic foot ulcer/s Primary objective “Gesundenuntersuchungs” cohort Estimation of the prevalence of prediabetes and unknown type 2 diabetes in people undergoing a health check-up (“Gesundenuntersuchung”). Prevalence of prediabetes (according to the guidelines of the Austrian Diabetes Association): -Fasting plasma glucose: 100mg/dL – 125 mg/dL or 5.6- 6.9 mmol/L -HbA1c: 39-47 mmol/mol or 5.7 – 6.4 % Prevalence of diabetes type 2 (according to the guidelines of the Austrian Diabetes Association) -Fasting plasma glucose: 126 mg/dL or higher -HbA1c: 48 mmol/mol or 6.5% or higher	—

Measure

Time frame

Primary outcome diabetes cohort The primary objective of the register is to characterize standard medical care and co-morbidities of people with type 2 diabetes in a primary care setting in Austria. Primary outcome measures: -Laboratory parameters: HDL-cholesterol, LDL-cholesterol, Triglycerides, Total cholesterol, HbA1c, Fasting plasma glucose, Creatinine, eGFR, Alanin-Aminotransferase (ALT), Aspartate-Aminotransferase (AST) -Medication :Glucose lowering medication, Lipid-lowering medication, Antihypertensive treatment, Antiplatelet therapy, Anticoagulants -Anthropometric and demographic data :Age, Sex, Weight, Height, Blood Pressure, Diabetes Duration, Smoking Behaviour -Comorbidities: Evaluation of circulatory abnormalities (peripheral vascular disease, stroke, coronary artery disease), arterial hypertension, heart failure, retinopathy, neuropathy, nephropathy (microproteinuria, macroproteinuria, nephrotic range proteinuria, renal failure), erectile dysfunction and diabetic foot ulcer/s Primary objective “Gesundenuntersuchungs” cohort Estimation of the prevalence of prediabetes and unknown type 2 diabetes in people undergoing a health check-up (“Gesundenuntersuchung”). Prevalence of prediabetes (according to the guidelines of the Austrian Diabetes Association): -Fasting plasma glucose: 100mg/dL – 125 mg/dL or 5.6- 6.9 mmol/L -HbA1c: 39-47 mmol/mol or 5.7 – 6.4 % Prevalence of diabetes type 2 (according to the guidelines of the Austrian Diabetes Association) -Fasting plasma glucose: 126 mg/dL or higher -HbA1c: 48 mmol/mol or 6.5% or higher

—

Secondary

Measure	Time frame
Secondary outcomes in both cohorts will be to evaluate the quality of life and physical activity of patients with type 2 diabetes in a primary care setting. Secondary outcome measures: - Quality of life - Physical functioning, physical role limitation, emotional role limitation, energy/fatigue, emotional wellbeing, social functioning, bodily pain and general health - Physical activity - Metabolic equivalent minutes per week	—

Measure

Time frame

Secondary outcomes in both cohorts will be to evaluate the quality of life and physical activity of patients with type 2 diabetes in a primary care setting. Secondary outcome measures: - Quality of life - Physical functioning, physical role limitation, emotional role limitation, energy/fatigue, emotional wellbeing, social functioning, bodily pain and general health - Physical activity - Metabolic equivalent minutes per week

—

Countries

Austria

Contacts

Public ContactHarald Kojzar

Medizinische Universität Graz

harald.kojzar@medunigraz.at+43 316 385 83544

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026